

Joanne de Hullu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/276525/publications.pdf>

Version: 2024-02-01

84
papers

2,163
citations

236925

25
h-index

254184

43
g-index

85
all docs

85
docs citations

85
times ranked

2463
citing authors

#	ARTICLE	IF	CITATIONS
1	Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. <i>Gynecologic Oncology</i> , 2016, 140, 8-14.	1.4	226
2	No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. <i>British Journal of Cancer</i> , 2007, 96, 1335-1342.	6.4	134
3	Paget disease of the vulva. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 60-74.	4.4	122
4	Surgery and radiotherapy in vulvar cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 38-58.	4.4	105
5	Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. <i>BMC Cancer</i> , 2015, 15, 593.	2.6	88
6	Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: A systematic review. <i>Gynecologic Oncology</i> , 2018, 148, 622-631.	1.4	83
7	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. <i>Journal of Clinical Oncology</i> , 2021, 39, 3623-3632.	1.6	69
8	Risk factors and treatment for recurrent vulvar squamous cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 1-13.	4.4	67
9	Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. <i>European Journal of Cancer</i> , 2016, 61, 137-145.	2.8	64
10	Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. <i>Gynecologic Oncology</i> , 2012, 127, 88-93.	1.4	61
11	Vulvar cancer: Two pathways with different localization and prognosis. <i>Gynecologic Oncology</i> , 2018, 149, 310-317.	1.4	60
12	Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas. <i>Human Mutation</i> , 2017, 38, 226-235.	2.5	55
13	Management of vulvar cancers. <i>European Journal of Surgical Oncology</i> , 2006, 32, 825-831.	1.0	53
14	Margin status revisited in vulvar squamous cell carcinoma. <i>Gynecologic Oncology</i> , 2019, 154, 266-275.	1.4	49
15	Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition. <i>Journal of the National Cancer Institute</i> , 2020, 112, 161-169.	6.3	47
16	Reactivation of Latent HPV Infections After Renal Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 1563-1573.	4.7	44
17	Vulvar Paget disease: A national retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 956-962.	1.2	44
18	Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1203-1211.	6.3	44

#	ARTICLE	IF	CITATIONS
19	Rare vulvar malignancies; incidence, treatment and survival in the Netherlands. <i>Gynecologic Oncology</i> , 2016, 142, 440-445.	1.4	39
20	NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract—A study of 24 cases from the Netherlands. <i>Gynecologic Oncology</i> , 2014, 134, 10-14.	1.4	35
21	BRCA1/2 mutation carriers are potentially at higher cardiovascular risk. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 159-171.	4.4	31
22	Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: Patients' and professionals' perspectives. <i>Gynecologic Oncology</i> , 2015, 136, 305-310.	1.4	31
23	Cardiovascular risk of BRCA1/2 mutation carriers: A review. <i>Maturitas</i> , 2016, 91, 135-139.	2.4	28
24	Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers. <i>Cancer</i> , 2018, 124, 952-959.	4.1	27
25	Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers. <i>JAMA Oncology</i> , 2021, 7, 1203.	7.1	27
26	Characteristics of Lynch syndrome associated ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 150, 324-330.	1.4	26
27	Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 1879-1891.	1.6	25
28	Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. <i>Gynecologic Oncology</i> , 2016, 143, 113-119.	1.4	23
29	Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome. <i>International Journal of Cancer</i> , 2020, 147, 478-489.	5.1	23
30	Clitoral involvement of squamous cell carcinoma of the vulva: Localization with the worst prognosis. <i>European Journal of Surgical Oncology</i> , 2015, 41, 592-598.	1.0	21
31	Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers. <i>Obstetrics and Gynecology</i> , 2016, 127, 1054-1063.	2.4	21
32	Limiting the morbidity of inguinofemoral lymphadenectomy in vulvar cancer patients; a review. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 615-624.	2.4	21
33	An alternative way to measure the depth of invasion of vulvar squamous cell carcinoma in relation to prognosis. <i>Modern Pathology</i> , 2015, 28, 295-302.	5.5	19
34	The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease. <i>JMIR Research Protocols</i> , 2017, 6, e178.	1.0	19
35	A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing. <i>Health Expectations</i> , 2018, 21, 659-667.	2.6	17
36	Surgical margins in squamous cell carcinoma, different for the vulva?. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1555-1561.	1.0	16

#	ARTICLE	IF	CITATIONS
37	Stop routine screening for associated malignancies in cutaneous noninvasive vulvar Paget disease?. <i>British Journal of Dermatology</i> , 2018, 179, 1315-1321.	1.5	16
38	Volume-controlled versus short drainage after inguinofemoral lymphadenectomy in vulvar cancer patients: A Dutch nationwide prospective study. <i>Gynecologic Oncology</i> , 2017, 146, 580-587.	1.4	15
39	Recommendations for diagnosing STIC: a systematic review and meta-analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 725-737.	2.8	15
40	The Paget Trial: topical 5% imiquimod cream for noninvasive vulvar Paget disease. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 250.e1-250.e8.	1.3	15
41	Somatic Mutation Profiling in Premalignant Lesions of Vulvar Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4880.	4.1	13
42	The efficacy of ultrasound in the follow up after a negative sentinel lymph node in women with vulvar cancer: a prospective single-centre study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 1461-1468.	2.3	13
43	Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 213-219.	1.4	11
44	Factors influencing decision-making around opportunistic salpingectomy: a nationwide survey. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e2.	2.2	11
45	Openness to new perspectives created by patient participation at the morbidity and mortality meeting. <i>Patient Education and Counseling</i> , 2021, 104, 343-351.	2.2	11
46	Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study. <i>Gynecologic Oncology</i> , 2021, 163, 117-124.	1.4	11
47	Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis. <i>Gynecologic Oncology</i> , 2022, 164, 221-230.	1.4	11
48	The immune cell infiltrate in the microenvironment of vulvar Paget disease. <i>Gynecologic Oncology</i> , 2018, 151, 453-459.	1.4	10
49	Radiotherapy is not indicated in patients with vulvar squamous cell carcinoma and only one occult intracapsular groin node metastasis. <i>Gynecologic Oncology</i> , 2021, 160, 128-133.	1.4	10
50	Primary prevention of ovarian cancer: a patient decision aid for opportunistic salpingectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2021, , .	1.3	10
51	Measuring the depth of invasion in vulvar squamous cell carcinoma: interobserver agreement and pitfalls. <i>Histopathology</i> , 2019, 75, 413-420.	2.9	9
52	Fallopian tube abnormalities in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 158, 339-346.	1.4	9
53	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). <i>JMIR Research Protocols</i> , 2021, 10, e24414.	1.0	9
54	Signal Transduction Pathway Activity in High-Grade, Serous Ovarian Carcinoma Reveals a More Favorable Prognosis in Tumors with Low PI3K and High NF- κ B Pathway Activity: A Novel Approach to a Long-Standing Enigma. <i>Cancers</i> , 2020, 12, 2660.	3.7	8

#	ARTICLE	IF	CITATIONS
55	Clonal Relationship Between Lichen Sclerosus, Differentiated Vulvar Intra-epithelial Neoplasia and Non HPV-related Vulvar Squamous Cell Carcinoma. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 151-160.	2.0	8
56	Patients'™ and professionals'™ perspectives on implementation of opportunistic salpingectomy: a mixed-method study. <i>BMC Health Services Research</i> , 2021, 21, 736.	2.2	8
57	Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites. <i>Oncotarget</i> , 2020, 11, 4570-4581.	1.8	7
58	Incidence and survival of glandular vulvar malignancies in the Netherlands. <i>Gynecologic Oncology</i> , 2017, 144, 553-557.	1.4	6
59	Disclosing Adverse Events in Clinical Practice: The Delicate Act of Being Open. <i>Health Communication</i> , 2022, 37, 191-201.	3.1	5
60	Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2022, 101, 56-67.	2.8	5
61	STop OVarian CAncer (STOPOVCA) young: Protocol for a multicenter follow-up study to determine the long-term effects of opportunistic salpingectomy on age at menopause. <i>Maturitas</i> , 2022, 159, 62-68.	2.4	5
62	Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2016, 115, 1174-1178.	6.4	4
63	Genetic counseling of patients with ovarian carcinoma: acceptance, timing, and psychological wellbeing. <i>Journal of Community Genetics</i> , 2020, 11, 183-191.	1.2	4
64	Ovarian cancer risk after salpingectomy for ectopic pregnancy or hydrosalpinx: results of the OCASE nationwide population-based database study. <i>Human Reproduction</i> , 2021, 36, 211-218.	0.9	4
65	Survival Is Related to Estrogen Signal Transduction Pathway Activity in Postmenopausal Women Diagnosed with High-Grade Serous Ovarian Carcinoma. <i>Cancers</i> , 2021, 13, 5101.	3.7	4
66	Sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma: a proposed protocol for a multicentre observational study. <i>BMC Cancer</i> , 2022, 22, 445.	2.6	4
67	Self-compassion, physical fitness and climacteric symptoms in oophorectomized BRCA1/2 mutation carriers. <i>Maturitas</i> , 2018, 108, 13-17.	2.4	3
68	Reduced morbidity by using LigaSure compared to conventional inguinofemoral lymphadenectomy in vulvar cancer patients: A randomized controlled trial. <i>Surgical Oncology</i> , 2020, 35, 149-155.	1.6	3
69	The rapid adoption of opportunistic salpingectomy at the time of hysterectomy for benign gynecological disease in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 948-949.	1.3	3
70	No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. <i>Journal of Cardiology</i> , 2021, 77, 570-575.	1.9	3
71	Healthcare professionals'™ perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups. <i>Familial Cancer</i> , 2023, 22, 1-11.	1.9	3
72	Low incidence of pulmonary metastases in vulvar cancer patients: limited value of routine chest imaging based on a cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 769-776.	2.3	2

#	ARTICLE	IF	CITATIONS
73	Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy. <i>Gynecologic Oncology</i> , 2021, 163, 371-377.	1.4	2
74	The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer. <i>Menopause</i> , 2021, Publish Ahead of Print, 1307-1312.	2.0	2
75	Patient involvement via videoconference at the morbidity and mortality (M&M) meeting during COVID-19. <i>BMJ Open Quality</i> , 2022, 11, e001691.	1.1	2
76	Reply: Familial ovarian screening: how to address abnormal TVU findings and its influence on the efficacy of screening?. <i>British Journal of Cancer</i> , 2006, 95, 1126-1127.	6.4	1
77	Vulvar squamous cell carcinoma. <i>Expert Review of Obstetrics and Gynecology</i> , 2009, 4, 659-672.	0.4	1
78	Cervical metastases originating from a primary rectal adenocarcinoma due to a pagetoid spread. <i>Human Pathology</i> , 2017, 68, 184-188.	2.0	1
79	Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors. <i>Supportive Care in Cancer</i> , 2022, 30, 3409-3418.	2.2	1
80	Vulvar cancer in hidradenitis suppurativa. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100929.	0.6	1
81	O26â€¦Optimal involvement of patients in the morbidity and mortality meeting (OPTIMA study). , 2019, , .		0
82	Abstract 741: Characterization of high-grade serous ovarian carcinoma by measuring functional signal transduction pathway activity. , 2021, , .		0
83	Clinicopathologic predictors of early relapse in advanced epithelial ovarian cancer: development of prediction models using nationwide data. <i>Cancer Epidemiology</i> , 2021, 75, 102008.	1.9	0
84	Reply to J. Zhang et al. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	0